THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Division of Pathology & Laboratory Medicine's Grand Rounds
Presents
"Optimizing dosing regimens for Erlotinib + Sulindac in a preclinical model of FAP"

Roderick H. Dashwood, B.Sc., M.Sc., Ph.D., FRSB
Director, Center for Epigenetics & Disease Prevention
Texas A&M College of Medicine
Institute of Bioscience & Technology
Houston, TX

Friday, October 4, 2019
8:00 a.m. – 9:00 a.m.
Russell Conference Room, G1.3741

Accreditation/Credit Designation:
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit* ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience and Educational Objectives:
After attending this activity, the target audience of Physicians from Pathology, Hematology, Cytology, Informatics, Trans Medicine, Clin Chemistry, Hematopathology, Lab Medicine, Cytogenetics, Flow Cytometry, Microbiology and Pathologists, Clin and Surgical Path Trainees, Med Techs should be able to:

- Utilize appropriate molecular testing and surgical pathology cases (knowledge, competence, performance, patient outcomes);
- Apply appropriate immunohistochemistry for tumor diagnosis and prognosis (knowledge, competence, performance, patient outcomes);
- Provide appropriate diagnostic information on specific tumor types to attending physicians (knowledge, competence, performance, patient outcomes);
- Provide appropriate use of blood products to attending physicians (knowledge, performance, competence, patient outcomes);
- Implement changes in laboratory work flow for rapid turnaround times for molecular diagnostics, clinical trials and patient care (knowledge, competence, performance, patient outcomes).

It is the policy of The University of Texas MD Anderson Cancer Center that the program chair(s), planning committee member, faculty/teacher/author, or CME activity reviewer must disclose any relevant financial relationships with commercial interests whose products may be discussed in the activities, if any. MD Anderson also requires that faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.